Protective efficacy of monoclonal antibodies to the capsule of carbapenem resistant Klebsiella

These mABs elicit phagocytic activity and protective immune response to clear bacteria from infected mice. Background: Carbapenem-resistant _K.pneumonia_ (CR-_Kp_) strains are a major threat worldwide due to the difficult to treat. Lack of new antibiotics in pipeline and the emergence of resistance to the last-resource antibiotics has resulted in an urgent need to develop novel treatment strategy. Such a treatment strategy would ideally be: 1. not susceptible to resistance development and, 2. specific to pathogenic organism without affecting microbiome.  Technology Overview: Researchers at Stony Brook University have developed an antibody based approach overcoming the problems associated with the use of antibiotics. The mABs bind to all clade 2 capsular polysaccharides of the carbapenem resistant ST258 Klebsiella clonal group. These mabs promote opsonophagocytic activity and bacterial killing in culture and were demonstrated to promote lung clearance and reduce dissemination of bacteria in infected mice. These mABs target 50-80% of strains of ST258 CR-Kp, the most abundant clone in the US. Clade 2 strains are associated with higher mortality (![Figure 1.]( fig1.png)). Further Details: Diago-Navarro et al. mBio 9 (2), e00091-18. 2018 Advantages: Highly specific to pathogen, leaves microbiome unaltered

Less likely to promote drug resistance

Protective against pulmonary infection model

Long serum half life of mABs results in reduced dosing frequency Applications: - Infectious diseases - Therapeutics - Diagnostics  8930  Intellectual Property Summary: Stage of Development: Licensing Potential: Licensing Status: Additional Information: carbapenem,monoclonal,antibody,infection,immune response,bacteria,pneumonia,antibiotic,resistance,pathogenic,microbiome,polysaccharide,bacterial,lung,pathogen,drug resistance,pulmonary,infectious,infectious disease,diagnostic,pulmonary infection,monoclonal antibody,mAbs,carbapenem antibiotic,antibiotic resistance,resistant bacteria,pathogenic bacteria,resistance mechanisms Please note, header image is purely illustrative. Source: Ðиколай СмолÑнкин, Wikimedia Commons, CC BY-SA 4.0.

Patent Information:
Technology/Start-up ID: